The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy
Objective: Propofol is the most widely administered intravenous anesthetic to induce deep sedation for gastroscopy procedures. Coadministration of nalbuphine can provide analgesia and sedation to patients experiencing visceral pain, thereby decreasing the amount of propofol needed and reducing the r...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1014486/full |
| _version_ | 1818020691567443968 |
|---|---|
| author | Lili Tang Chenxuan Ye Nan Wang Chen Chen Sirui Chen Shan Gao Xuesheng Liu |
| author_facet | Lili Tang Chenxuan Ye Nan Wang Chen Chen Sirui Chen Shan Gao Xuesheng Liu |
| author_sort | Lili Tang |
| collection | DOAJ |
| description | Objective: Propofol is the most widely administered intravenous anesthetic to induce deep sedation for gastroscopy procedures. Coadministration of nalbuphine can provide analgesia and sedation to patients experiencing visceral pain, thereby decreasing the amount of propofol needed and reducing the risk of propofol-induced adverse events. We carried out this study to determine the median effective dose (ED50) of propofol in combination with different dosages of nalbuphine and the optimal dosage of nalbuphine during painless gastroscopy.Methods: We recruited sixty-five patients aged 18–60 years who underwent elective painless gastroscopy. A total of sixty-one patients were allocated randomly to the N1 group (nalbuphine 0.1 mg/kg) or N2 group (nalbuphine 0.15 mg/kg). Three minutes after administration of nalbuphine, patients received a preset dose of propofol at 2.0 mg/kg with a dose gradient of 0.2 mg/kg according to Dixon’s “up-and-down” method. The primary outcome was the ED50 of propofol in combination with nalbuphine. Hemodynamic parameters, recovery time, pain score, and adverse events were recorded as secondary outcomes.Results: The ED50 of propofol in the N2 group was significantly lower than that observed in the N1 group (p < 0.01). Using probit analysis, the ED50 and ED95 of propofol were 1.632 mg/kg and 2.759 mg/kg in the N1 group and 1.111 mg/kg and 2.243 mg/kg in the N2 group, respectively. The incidence of hypotension in the N2 group was lower than that in the N1 group (p < 0.05), and the recovery time was shorter than that of the N1 group (p < 0.05).Conclusion: In adult patients, 0.15 mg/kg nalbuphine led to a significant reduction in the ED50 and ED95 of propofol during gastroscopy. This dose of nalbuphine also reduced the incidence of hypotension and shortened the recovery time. Therefore, nalbuphine (0.15 mg/kg) combined with propofol is a safe option for enhancing recovery after painless gastroscopy in adult patients.Clinical Trial Registration: [https://www.chictr.org.cn/edit.aspx?pid=126699&htm=4], identifier [ChiCTR2100053204]. |
| first_indexed | 2024-04-14T08:08:53Z |
| format | Article |
| id | doaj.art-3dd7ac5d3fd94b61a4e53e6a1b71049e |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-14T08:08:53Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3dd7ac5d3fd94b61a4e53e6a1b71049e2022-12-22T02:04:37ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.10144861014486The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopyLili Tang0Chenxuan Ye1Nan Wang2Chen Chen3Sirui Chen4Shan Gao5Xuesheng Liu6Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Biomedical Engineering, City University of Hong Kong, Kowloon Tong, Hong Kong SAR, ChinaDepartment of Pharmacology, Basic Medical College, Anhui Medical University, Hefei, ChinaDepartment of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaObjective: Propofol is the most widely administered intravenous anesthetic to induce deep sedation for gastroscopy procedures. Coadministration of nalbuphine can provide analgesia and sedation to patients experiencing visceral pain, thereby decreasing the amount of propofol needed and reducing the risk of propofol-induced adverse events. We carried out this study to determine the median effective dose (ED50) of propofol in combination with different dosages of nalbuphine and the optimal dosage of nalbuphine during painless gastroscopy.Methods: We recruited sixty-five patients aged 18–60 years who underwent elective painless gastroscopy. A total of sixty-one patients were allocated randomly to the N1 group (nalbuphine 0.1 mg/kg) or N2 group (nalbuphine 0.15 mg/kg). Three minutes after administration of nalbuphine, patients received a preset dose of propofol at 2.0 mg/kg with a dose gradient of 0.2 mg/kg according to Dixon’s “up-and-down” method. The primary outcome was the ED50 of propofol in combination with nalbuphine. Hemodynamic parameters, recovery time, pain score, and adverse events were recorded as secondary outcomes.Results: The ED50 of propofol in the N2 group was significantly lower than that observed in the N1 group (p < 0.01). Using probit analysis, the ED50 and ED95 of propofol were 1.632 mg/kg and 2.759 mg/kg in the N1 group and 1.111 mg/kg and 2.243 mg/kg in the N2 group, respectively. The incidence of hypotension in the N2 group was lower than that in the N1 group (p < 0.05), and the recovery time was shorter than that of the N1 group (p < 0.05).Conclusion: In adult patients, 0.15 mg/kg nalbuphine led to a significant reduction in the ED50 and ED95 of propofol during gastroscopy. This dose of nalbuphine also reduced the incidence of hypotension and shortened the recovery time. Therefore, nalbuphine (0.15 mg/kg) combined with propofol is a safe option for enhancing recovery after painless gastroscopy in adult patients.Clinical Trial Registration: [https://www.chictr.org.cn/edit.aspx?pid=126699&htm=4], identifier [ChiCTR2100053204].https://www.frontiersin.org/articles/10.3389/fphar.2022.1014486/fullnalbuphinepropofolgastroscopydose-effect relationshipED50 |
| spellingShingle | Lili Tang Chenxuan Ye Nan Wang Chen Chen Sirui Chen Shan Gao Xuesheng Liu The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy Frontiers in Pharmacology nalbuphine propofol gastroscopy dose-effect relationship ED50 |
| title | The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy |
| title_full | The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy |
| title_fullStr | The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy |
| title_full_unstemmed | The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy |
| title_short | The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy |
| title_sort | median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy |
| topic | nalbuphine propofol gastroscopy dose-effect relationship ED50 |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1014486/full |
| work_keys_str_mv | AT lilitang themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT chenxuanye themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT nanwang themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT chenchen themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT siruichen themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT shangao themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT xueshengliu themedianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT lilitang medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT chenxuanye medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT nanwang medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT chenchen medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT siruichen medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT shangao medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy AT xueshengliu medianeffectivedosesofpropofolcombinedwithtwodifferentdosesofnalbuphineforadultpatientsduringpainlessgastroscopy |